Rationale: Activation of liver X receptors (LXRs) inhibits the progression of atherosclerosis and promotes regression of existing lesions. In addition, LXR␣ levels are high in regressive plaques. Macrophage arginase 1 (Arg1) expression is inversely correlated with atherosclerosis progression and is markedly decreased in foam cells within the lesion.
A therosclerosis results from disrupted lipid homeostasis as well as chronic inflammation involving a number of immune pathways. 1 As cells involved in both lipid and immune processes, macrophages play a key role throughout atherogenesis from initiation and fatty streak formation to plaque rupture. 2 In addition to dissecting the progression of atherosclerosis, there is a growing interest in the mechanisms leading to the regression (or reduced volume) of established atherosclerotic lesions. In humans, plaque regression occurs when LDL-cholesterol levels are aggressively reduced by high doses of statins and/or when HDL-cholesterol is increased. 3 To identify pathways leading to lesion regression, a number of experimental models have now been developed. 3 In one such model, a segment of plaque-containing aorta from a hyperlipidemic apolipoprotein E-deficient (apoE Ϫ/Ϫ ) mouse is transplanted into a wild-type (WT) recipient, thereby rapidly improving abnormal lipid levels and inflammatory environment. 4 In this setting, plaques in the WT recipients undergo a substantial reduction in their foam cell content while increasing the number of smooth muscle cells present in the fibrous cap, consistent with the stabilization and regression of the plaque. Even though the underlying mechanisms and factors involved in atherosclerosis regression are not fully understood, it appears that CD68ϩ cells of monocytic origin play an important role. In these cells, the chemokine (C-C motif) receptor 7 (CCR7) is induced and functions as a key regulator of plaque regression. [5] [6] [7] The liver X receptors (LXRs) of the nuclear receptor family are important regulators of macrophage biology. 8 Both LXR␣ and LXR␤ (NR1H3 and NR1H2, respectively) are activated by oxysterols and by synthetic agonists such as T0901317 (T1317) or GW3965. LXRs induce gene expression by heterodimerizing with the 9-cis retinoid X receptor (RXR) and binding to a DNA motif termed LXR response element (LXRE), in regulatory regions of LXR target genes. 9 LXRs also inhibit target gene expression either by antagonizing the activities of other transcription factors 10 or by inhibiting the release of corepressor complexes from target gene promoters. 11 LXRs mediate the prominent antiatherosclerotic effects of LXR agonists by activating genes that promote cholesterol efflux, reducing macrophage and lymphocyte activation, inhibiting smooth muscle cell proliferation, and downregulating the expression of endothelial adhesion molecules. 8, 12, 13 Treatment of apoE Ϫ/Ϫ or LDL receptor (LDLR) Ϫ/Ϫ atherosclerosis mice models with LXR agonists substantially decreases the development of lesions, and ablation of LXRs in hematopoietic cells in these models increases aortic lesion area. 8 Moreover, LXRs play an important role as modulators of atherosclerosis regression. LXR agonists promote lesion regression in the ApoE*3Leiden mouse model fed a cholesterol-free diet, which is associated with an increase in CCR7 expression and reduced endothelial monocyte adherence. 7 Likewise, LXRs are required for the CCR7 increase in CD68ϩ cells and for the maximal CCR7-mediated regression of atherosclerotic lesions in the plaque transplantation regression model. 5 In addition to CCR7, LXRs may regulate the expression of other important modulators of macrophage biology in lesions undergoing regression. Arginase (Arg)1 catalyzes the hydrolysis of L-arginine to urea and L-ornithine, a precursor for the synthesis of collagen and polyamines, which may contribute to plaque stabilization and tissue repair. 14, 15 Several lines of evidence point to an antiatherosclerotic role for macrophage Arg1. Enhanced levels of this enzyme in macrophages are associated with reduced atherosclerosis in rabbits. 16 Moreover, in human atherosclerotic plaques, Arg1 protein is mainly present in macrophages and non-lipid-laden cells adjacent to the arterial lumen but not in cells surrounding the atherosclerotic lipid core. 17 Macrophage Arg1 expression is regulated in response to anti-inflammatory cytokines, such as interleukin (IL)-4 and IL-10. 18 STAT6, CAAT/enhancer binding protein-␤, and the Ets family transcription factor PU.1 cooperate to regulate the IL-4 -dependent induction of Arg1 gene by binding to a series of sites located 3 kb upstream of its transcription start site. 18, 19 Macrophage Arg1 mRNA levels are also induced by the nuclear receptors peroxisome proliferator-activated receptor (PPAR)␥ and PPAR␦. 20 -22 In the present study, we demonstrate that Arg1 is highly expressed in CD68ϩ cells from regressive lesions in a transplant model and dissect the role of LXR␣ on the regulation of Arg1 expression in cultured macrophages as well as in the regressive atherosclerotic plaque. This work not only implicates LXR␣ in the regulation of Arg1 during atherosclerosis regression but also uncovers a novel mechanism by which LXR␣ modulates gene expression.
Methods
Further details regarding the materials and procedures are provided in the Online Supplemental Information available at http://circres. ahajournals.org.
Aortic Plaque Transplantation
Aortic transplant experiments were carried out as previously described. 6, 23 ApoE Ϫ/Ϫ mice fed a Western diet for 16 weeks were divided into a pretransplant group for baseline analysis or a group of donors of aortic arches. Recipients were maintained on a standard chow diet and euthanized 3 days after transplantation. Laser capture microdissection was performed as described. 6 All procedures were approved by the Animal Care and Use Committee at New York University School of Medicine.
Transient Transfections
RAW-VO cells transfected with pXP2-ARG1prom, pCMV-␤-Galactosidase, pcDNA3.1, or pcDNA3.1-FLAG-hLXR␣ using Turbofect (Fermentas) for 24 hours were treated with 10% fetal bovine serum containing DMEM and vehicle (dimethyl sulfoxide) or T1317 (1 mol/L) for 18 hours, followed by incubation with or without IL-4 (10 ng/L) for another 6 hours, and luciferase and ␤-galactosidase activities were measured.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation experiments were performed as described, 24 except that cells were cross-linked with 1.5 mmol/L of ethylene glycol-bis(succinimidylsuccinate) for 20 minutes, followed by 10 minutes with 1% formaldehyde solution. The antibodies used were LXR␣ (ab41902), PU.1 (sc-352), heat shock protein 90 kDa (sc-59577), and IRF8 (sc-6058). The Arg1, ABCA1, or IRF8 gene promoters were amplified with primers shown in Online Table I.
RNA Analysis
RNA reverse transcription was performed with the use of a cDNA synthesis kit (Roche) and quantified by PCR, using the Brilliant Table I ).
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RNA Interference
Assays were performed as previously described. 24 RAW-LXR␣ cells were transfected by the Amaxa Nucleofector with 300 pmol of either the siControl nontargeting pool or the SMARTpool siRNA mouse PU.1 (L-041420) and IRF8 (L-040737) (Dharmacon). Cells were treated as in the transfection experiments.
Results
Arg1 Expression Is Enhanced in Regressive Atherosclerotic Lesions
Arg1 is expressed in several cell types in the arterial wall such as smooth muscle cells, endothelial cells, or macrophages. 14 To address the regulation of Arg1 expression in progressive versus regressive lesions, we used a previously validated surgical transplant atherosclerosis model. 4 In this model, the size of apoE Ϫ/Ϫ mice plaques decreases by 40% and lipidloaded cell content by 75% when transplanted to WT mice but continues to progress when transplanted into apoE Ϫ/Ϫ mice. 6 Thus, lesions from the thoracic aorta in the apoE Ϫ/Ϫ mice were transplanted into abdominal aortic segments of either apoE Ϫ/Ϫ or WT mice ( Figure 1A ). As control, RNA from CD68ϩ cells from donor plaque lesions was isolated by laser capture microdissection (LCM), analyzed, and labeled as baseline ( Figure 1) . No difference in Arg1 expression was observed between CD68ϩ cells from baseline or apoE Ϫ/Ϫ recipient mice (progressive plaques), whereas Arg1 levels were dramatically induced in CD68ϩ cells from lesions transplanted to WT mice (regressive plaques) ( Figure 1B and Online Figure I ). These results demonstrate that Arg1 gene expression is dynamically regulated within atherosclerotic lesions and is markedly enhanced in plaques subject to a regressive environment.
LXR␣ Induces Macrophage Arg1 Expression
Because ligand-activated LXR␣ inhibits atherogenesis 25, 26 and is highly induced in CD68ϩ cells from plaques undergoing regression, 6 we next explored the possibility that LXR␣ regulates Arg1 expression in macrophages. We first determined Arg1 mRNA levels in the macrophagederived LXR␣-deficient RAW264.7 cell line transduced with either FLAG-LXR␣ (LXR␣) or an empty retroviral vector (VO) 24 treated with the LXR ligand T1317. Because Arg1 expression is strongly modulated by IL-4 and the molecular mechanism underlying this regulation has been characterized in detail, 18, 19 we also examined whether IL-4 -induced levels of Arg1 could be regulated by the LXR ligand ( Figure 2A ). Arg1 mRNA levels were induced by T1317 compared with vehicle treatment in RAW-LXR␣ cells but not in RAW-VO cells (Figure 2A , inset). In agreement with previous reports, 19 Arg1 expression was induced by IL-4 in both cell lines; however, this IL-4 induction was synergistically enhanced in the presence of T1317 in an LXR␣-dependent manner. In addition, Arg1 protein was also induced by T1317 ( Figure 2B , upper panel) and more potently by a combination of IL-4 and T1317 or GW3965 ( Figure 2B , lower panel). Similar results were obtained in bone marrow-derived macrophages, which express LXR␣ (Online Figure II) . Altogether, these data show that both mRNA and protein expression of Arg1 are enhanced by LXR␣ activation in cultured macrophages.
Arg1 Expression in Regressive Plaques Requires LXR␣
To examine the role of myeloid LXR␣ expression on Arg1 levels in regressive lesions, we compared Arg1 levels in CD68ϩ cells from WT recipient mice that had been transplanted with plaques from apoE Ϫ/Ϫ donors repopulated with either apoE Ϫ/Ϫ or apoE Ϫ/Ϫ LXR␣ Ϫ/Ϫ bone marrow ( Figure  2C ). Arg1 expression in regressive plaques was severely impaired in lesions from donor mice lacking LXR␣ expression in their myeloid cells ( Figure 2C ), and this reduced Arg1 expression was associated with less plaque regression. 5 These data indicate that LXR␣ is important in the regulation of Arg1 expression in vivo, within atherosclerotic plaques undergoing regression. Arg1 competition with nitric oxide synthase (NOS) for their common substrate decreases nitric oxide (NO) production. 14, 15 Macrophage expression of the inducible form of NOS (iNOS) is proatherogenic. 27 Thus, an increase in Arg1 expression leading to lower NO levels in these cells may result in plaque reduction. As a first attempt to elucidate the functional relevance of LXR-induced Arg1 levels, we evaluated the levels of NO in LXR ligand-treated macrophages on stimulation with lipopolysaccharide ( Figure  2D and Online Figure III) . In lipopolysaccharide-treated cells, LXR␣-induced Arg1 expression was associated with a reduction in NO production, and the combination of IL-4 and LXR ligand further diminished NO levels significantly. Interestingly, this occurred in the absence of changes in the expression of iNOS (Online Figure III) , which can also be subject to regulation by LXR, 12 indicating that the observed changes in NO are unlikely to be due to LXR modulation of iNOS expression. Thus, LXR␣-mediated induction of Arg1 correlates with reduced NO levels, which may in turn affect the progression of the atherosclerotic lesion.
Arg1 Regulation by LXR␣ Is Mediated by PU.1
We next examined the regulation of a luciferase reporter gene driven by a 4.8-kb fragment of the Arg1 region upstream of the transcription start site. 19 As shown in Figure 3A , Arg1 reporter activity was enhanced when cells were activated with T1317 only in the presence of transiently overexpressed LXR␣. As expected, Arg1 reporter activity was induced by IL-4 regardless of LXR␣ expression. Furthermore, the activity of this Arg1 reporter was further increased in an LXR␣dependent manner when cells were cotreated with T1317 and IL-4 compared with IL-4 or T1317 alone. The absence of LXR ligand responsiveness in RAW264.7 cells, which endogenously express LXR␤ in the absence of LXR␣, indicates that the levels of LXR␤ present in these cells may not be sufficient to drive Arg1 promoter activity because both isotypes are capable of being activated by the T1317 ligand. However, overexpression of LXR␤ above the endogenous levels induced Arg1 reporter activity, albeit to a lower extent compared with LXR␣ (Online Figure IV) , indicating that both isotypes when present at high levels are able to stimulate Arg1 transcription. Positive regulation of target genes by LXRs often involves the binding of the LXR/RXR heterodimer to an LXRE. 9 To were transplanted into WT recipients. RNA from CD68ϩ cells was isolated and analyzed for Arg1 mRNA levels as described in Figure  1 . Fold changes are presented relative to baseline apoE Ϫ/Ϫ donors, which was set as 1 (not shown, t test; apoE Ϫ/Ϫ versus apoE Ϫ/Ϫ LXR␣ Ϫ/Ϫ : *PϽ0.001). D, RAW-LXR␣ cells were treated with vehicle (dimethyl sulfoxide) or LXR agonists T1317 (T) and/or IL-4 for 48 hours. Cells were then stimulated with 100 ng/mL lipopolysaccharide. After 24 hours, NO production was measured. Data are meanϮSD (nϭ3). *PϽ0.05.
identify an LXRE, a series of truncated Arg1 reporter constructs were assayed for their response to ligand-activated LXR␣. Ligand-dependent increase of Arg1 reporter activity was abolished only when the Ϫ0.336 kb Arg1 reporter was used ( Figure 3A ), suggesting that the LXR-responsive region is located between 0.8 kb and 0.336 kb upstream of the Arg1 transcription start site. However, no LXRE was predicted in that region by MatInspector. Recruitment of LXR␣ was further investigated by chromatin immunoprecipitation in RAW-LXR␣ macrophages using RAW-VO cells as negative control (Online Figure V) . As expected, LXR␣ bound to the promoter of ABCA1, a well-characterized LXR target gene (Online Figure VA) but not to the Ϫ0.8/Ϫ0.3 kb region in the Arg1 promoter (Online Figure VB) . These data suggest that LXR␣ may not regulate Arg1 expression by a classic LXREbinding mechanism and that instead, additional LXRdependent pathways may be involved.
Analysis of the Ϫ0.8/Ϫ0.3 kb Arg1 sequence revealed a PU.1 site situated at Ϫ0.7 kb ( Figure 3B ). PU.1 is already known to enhance Arg1 expression by binding to sites located around Ϫ3 kb in an Arg1 enhancer. 18 Thus, we speculated that Arg1 regulation by LXR␣ might be mediated through PU.1 and assessed PU.1 binding to the Ϫ0.7 kb sequence. In RAW-VO cells, PU.1 occupied the Ϫ3 kb region in the Arg1 promoter as expected, as well as the Ϫ0.7 kb site in an LXR ligand-independent manner ( Figure 3B ). Only in RAW-LXR␣ cells, the presence of LXR␣ ligand dramatically increased PU.1 binding to the Ϫ0.7 kb site but not to the Ϫ3 kb site. Hence, PU.1 binds to an additional site in the Arg1 promoter in an LXR␣-and T1317-regulated manner.
To determine whether the LXR␣-dependent increase in Arg1 expression is mediated by PU.1, RAW-LXR␣ cells were transfected with control siRNA oligonucleotides or siRNA targeting PU.1, which efficiently decreased PU.1 protein levels ( Figure 3C ). PU.1 silencing led to a dramatic decrease (ϳ70%) in the Arg1 induction by T1317 and T1317/IL-4 ( Figure 3C and Online Figure VIA) . Conversely, PU.1 overexpression in the presence of LXR␣ potentiated the basal and T1317-induced Arg1 reporter activity ( Figure  3D ). Altogether, these results strongly suggest that PU.1, in concert with LXR␣, mediates the LXR ligand-dependent activation of Arg1 expression through a novel element localized 0.7 kb upstream the Arg1 transcription start site.
LXR␣ Enhances IRF8 Binding to the ؊0.7 kb Site in the Arg1 Promoter
PU.1 exerts its transcriptional activity with other partners, including the interferon regulatory factor 8 (IRF8). 28 IRF8 is a member of the IRF transcription factor family and is implicated in B-cell 29 and macrophage 30 differentiation during hematopoiesis. Thus, we speculated that LXR␣ might enhance PU.1 binding to the Ϫ0.7 kb site ( Figure 3A) by facilitating the recruitment of IRF8. As shown in Figure 4A , IRF8 weakly binds to the Ϫ0.7 kb site in both cell lines. In RAW-LXR␣ cells, however, IRF8 basal occupancy at the Ϫ0.7 kb site is markedly enhanced by the LXR ligand. Interestingly, we also observed a strong binding of IRF8 at Ϫ3 kb irrespective of LXR␣ or ligand treatment. These different modes of binding possibly reflect the different sequence of these sites (see Figure 6 and Discussion). We also examined whether Arg1 regulation by LXR ligands is affected by IRF8. Reduction of IRF8 levels by specific siRNA oligonucleotides led to a marked decrease in the LXR ligand-induced expression of Arg1 ( Figure 4B ), whereas the expression of another well-characterized LXR target gene such as ABCA1 remained unaffected (Online Figure VIB) . Altogether, these results demonstrate that IRF8 occupancy to the Ϫ0.7 kb site in the Arg1 promoter is specifically enhanced by ligand-activated LXR␣ and identifies IRF8 as a novel regulator of Arg1 expression. Further analysis of the sequence at Ϫ0.7 kb revealed the presence of an Ets/IRF composite element ( Figure 6 ). Such an element consists of a PU.1 and an IRF element separated by 2 nucleotides and can be bound by either PU.1/IRF8 or PU.1/IRF4 heterodimers. 31 Similar composite sites are present in the promoters of genes involved in immune signaling such as IL-1␤ 32 and TLR4, 33 among others. To confirm that this sequence within the Arg1 promoter is indeed responsible for its regulation by LXR, luciferase assays were performed using a reporter in which both PU.1 and IRF8 half-sites were mutated. As shown in Figure 4C , LXR ligand-induced Arg1 promoter activity was abrogated when the composite element was disturbed, indicating that this is the bona fide LXR-responsive sequence.
LXR␣ Enhances IRF8 Expression
To dissect the molecular mechanism by which LXR␣ facilitates IRF8 and PU.1 binding to the Arg1 promoter, immunoprecipitation studies were performed and demonstrated that IRF8 interaction with PU.1 occurs in an LXR␣-dependent manner ( Figure 4D ). The formation of the PU.1/IRF8 complex correlated with an increase in IRF8 levels in LXR␣-expressing cells. Thus, we next investigated in more detail whether LXR␣ regulates the expression of PU.1, IRF8, or both. We examined PU.1 and IRF8 mRNA levels in T1317treated and/or IL-4 -treated cells. Although the expression of PU.1 was unchanged (Online Figure VII) , IRF8 mRNA and protein levels were increased in LXR␣-expressing macrophages treated with T1317 ( Figure 5A and 5B and Online Figure VII ). Furthermore, in silico analysis of the IRF8 locus revealed the presence of an LXRE located 20 kb upstream the IRF8 gene transcription start site. Using RAW-VO cells as negative control, we confirmed that LXR␣ specifically binds to the Ϫ20 kb site ( Figure 5C ). Thus, our findings suggest that the regulation of IRF8 expression by LXR␣ probably occurs through an LXRE in a distal sequence of the IRF8 gene.
Discussion
To design strategies aimed at promoting the regression of established atherosclerotic lesions, the mechanisms and factors regulating this process must be defined. Recently, the emigration of monocytic-derived cells from plaques was described as an important feature of plaque regression, and LXR␣ was shown to play a key role in this process by inducing the expression of the chemokine receptor CCR7. Our study demonstrates that Arg1 expression is also markedly induced in CD68ϩ cells from regressive lesions in a regression transplant model, which is consistent with a recent study showing Arg1 expression in regressive atherosclerotic lesions in "Reversa" mice (Ldlr Ϫ/Ϫ Apob 100/100 Mttp fl/fl Mx1Cre ϩ/ϩ ) 34 and Figure 3B . IRF8 occupancy was determined by chromatin immunoprecipitation assays. Primers amplifying the Ϫ5 kb (1), Ϫ3 kb (2), or Ϫ0.7 kb (3) sites were used. Shown is a representative experiment of nϭ4. B, RAW-LXR␣ cells were transfected with control or IRF8 siRNAs and treated as in Figure 3 . IRF8 and heat shock protein 90 kDa and Arg1 expression were analyzed as in Figure 3C . Values indicate expression normalized to cyclophilin and are presented relative to the expression in siRNA-control vehicle-treated cells, which is set as 1. Data are meanϮSD (nϭ3). C, Bone marrow-derived macrophages from WT or IRF8 Ϫ/Ϫ mice were cultured with T1317 (T) (1 mol/L) for 72 hours. Expression of the indicated proteins was analyzed by immunoblotting. D, RAW264.7 cells were transfected as in Figure 3 . For each reporter, luciferase and ␤-galactosidase activities were measured and the ratio was compared with the vehicle-treated condition in the absence of LXR␣ (Ϫ), which was set as 1. Data are meanϮSD (nϭ3). D, RAW-VO or LXR␣ cells were incubated with dimethyl sulfoxide or LXR agonist T for 24 hours. IRF8 was immunoprecipitated and IRF8-containing complexes were resolved by SDS-PAGE.
with earlier reciprocal findings that Arg1 levels are substantially decreased in foam lipid-loaded cells within progressive lesions. 17 Our work also identifies LXR␣ as an important modulator of Arg1 expression both in vitro and in vivo. Moreover, Arg1 levels are induced in lipid-laden macrophages, as expected from previous reports, 20 -22 and, intriguingly, LXR␣ is able to induce Arg1 expression in these cells (Online Figure IIB) . This regulation of Arg1 expression in cultured loaded macrophages is somehow contradictory to a study showing weak Arg1 levels in foam cells within the plaque. 17 In the present report, we focus on the regulation of Arg1 by LXR␣ in regressive lesions, and additional experiments will be required to establish whether LXR␣ induces Arg1 levels in plaques undergoing atherosclerosis progression.
Arg1 may affect plaque regression. As mentioned, Arg1 decreases the production of NO, 14, 15 which, when synthesized in macrophages, is proatherogenic. 27 Therefore, a shift in L-arginine availability for macrophage iNOS caused by enhanced Arg1 levels may result in reduced atherosclerosis. Indeed, our studies show that in cultured macrophages, LXR␣-induced Arg1 expression correlates with a decrease in NO production, whereas iNOS levels remain unaffected ( Figure 2D and Online Figure III ). In addition, pilot studies suggest that altered NO levels in these cells are mainly due to Arg1, because even in the absence of the second arginase isoform, Arg2, activation of LXR␣ leads to decreased NO levels (B. Pourcet, A. Hobbs, and I. Pineda-Torra, unpublished observations). Whether these changes in NO production may lead to plaque reduction awaits further investigation.
An increase in macrophage Arg1 levels has also been shown to be associated with enhanced vascular smooth muscle cell proliferation, 35 which may contribute to the remodeling of the fibrous cap surrounding the atherosclerotic lesion and thus to plaque stabilization. 36 Interestingly, in the transplant regression model used in our study, regressing plaques also present an increased number of smooth muscle cells, particularly in the fibrous cap. 37 Therefore, an induction in macrophage arginase expression may modulate atherosclerosis regression in part by increasing the stability of the plaque. The impact of Arg1 function on atherosclerosis, however, may be cell type-dependent. In endothelial cells, NO limits atherosclerosis progression 38 and thus inhibition of arginase activation, and specific knockdown of Arg2 in the endothelium reduces atherosclerosis progression. 39 Antiatherogenic therapies based on arginase inhibition have been proposed. 40 However, because LXR␣ activates Arg1 expression through PU.1 and IRF8 (Figure 3, 4) , factors exclusively expressed in myeloid-and lymphoid-derived cells, 31 it is likely that LXR␣ induction of Arg1 expression is restricted to these cells. Consistent with this, Arg1 is mainly present in CD68ϩ cells within the regressive atherosclerotic plaque, where LXR␣ is also abundantly expressed, 5 whereas only a few endothelial cells lining the lesion appear to express the Figure  2A . B, Both cell lines and bone marrow-derived macrophages were treated with vehicle or T1317 (T) (1 mol/L) for 48 hours. IRF8 and heat shock protein 90 kDa were measured by Western blotting. C, Upper panel: Location of a novel LXRE in the IRF8 locus. Primer pairs used to amplify an upstream Ϫ50 kb region that serves as an additional negative control (1) and the Ϫ20 kb site (2) are shown. Lower panel: RAW-VO and RAW-LXR␣ cell lines incubated with T (1 mol/L) for 2 hours. LXR␣ occupancy was determined by chromatin immunoprecipitation assays with primers amplifying the indicated sites. Values were normalized to input chromatin and to signal from RAW-VO cells, which was considered as background and set as 1. Shown is a representative experiment of nϭ3. Figure I) . By contrast, the expression of Arg2, which is an LXR target gene regulated by a classic LXRE-binding mechanism, 41 is altogether absent from regressive lesions, suggesting that regulation of Arg2 within the plaque is more complex and probably requires additional factors.
enzyme (Online
Our results establish that LXR␣ does not bind to the Arg1 promoter but instead regulates Arg1 levels by promoting the binding of the hematopoietic transcription factors IRF8 and PU.1 to a novel site located 0.7 kb upstream of the transcription start site in the Arg1 gene. Previous work established that the PU.1/IRF complex is formed before it binds to the promoter and is stabilized by PU.1 phosphorylation. 32, 42, 43 Our own immunoprecipitation studies show that the PU.1/ IRF8 interaction is enhanced in the presence of LXR␣ ( Figure 4D ), probably in part by inducing the levels of IRF8 expression. Whether this receptor also promotes the binding of PU.1 to other members of the IRF family remains to be investigated.
A different role for PU.1 in LXR target gene expression was shown in a previous study. 44 A large proportion of LXR␤ sites in macrophages are within 100 bp of PU.1 elements, and their occupancy requires PU.1. Thus, regulation of a subset of LXR␤ target genes (which are also targets for LXR␣) is PU.1-dependent. 44 In that report, however, LXR target gene transcription is mediated through binding of each transcription factor (LXR and PU.1) to their respective sites. In this case, PU.1 primes the binding of LXR to its response elements by facilitating the deposition of monomethylated histone marks through collaboration with other yet unknown factors. Interestingly, our data demonstrate that reciprocally, LXR␣ can modify the binding of PU.1 to certain sequences, such as the composite Ϫ0.7 kb site in the Arg1 locus, which are bound by PU.1 in an LXR␣dependent manner ( Figure 3B ), apparently without LXR␣ binding (Online Figure V) .
Our findings further reveal IRF8 as an important component of the regulation of macrophage Arg1 expression and its regulation by LXR ligands. Interestingly, Arg1 expression appears to be particularly sensitive to IRF8 because an approximately 40% reduction in IRF8 levels results in markedly reduced Arg1 mRNA (Figure 4 and Online Figure VI, D). Consistent with this, pilot studies show that Arg1 levels are dramatically reduced in primary macrophages from IRF8 Ϫ/Ϫ mice even if PU.1 expression remains unaffected (B. Pourcet, X. Xu, and I. Pineda-Torra, unpublished observations). Intriguingly, IRF8 and PU.1 are regulated by each other: The expression of each partner in the heterodimer is induced when the other one is knocked down while nevertheless dampening basal as well as LXR ligand-induced levels of Arg1 (Online Figure VI, C and D) . In concert, these experiments suggest that PU.1 probably requires IRF8 to fully induce the Arg1 promoter and enhance Arg1 expression. Whereas the repression of PU.1 by IRF8 has been documented in B cells, 29 the reciprocal inhibition of IRF8 by PU.1 is novel. Additional analysis will be required to elucidate the molecular basis of this repression. Similar to PU.1, IRF8 shows a bimodal binding preference regarding its dependency on LXR␣ ( Figure 4A ). Unlike the Ϫ0.7 site, IRF8 binds the Ϫ3 kb in an LXR␣-independent manner, despite the absence of an IRF putative binding sequence. This is in agreement with IRF8 binding to STAT or IFN-␥ activation sites 45 and to Ets sites through protein-protein interactions with unidentified factor(s). 46 Because sites for other transcription factors such as STAT or Ets are present in the Ϫ3 kb region, 18, 19 IRF8 may bind to this region by interacting with such factors. Further studies are needed to determine whether, similar to Arg1, expression of other macrophage LXR targets are regulated through IRF8.
We also provide evidence that the increase in IRF8 expression by LXR ligands is through LXR␣ binding to a distant upstream site, thereby establishing IRF8 as a novel LXR␣ target gene. LXRs modulate the activity or expression of other IRF family members. Indeed, LXRs prevent the binding of IFN-␥-activated phospho-STAT1 to the IRF1 promoter, thereby suppressing IRF1 expression, 47 and inhibit IRF3 activation, leading to the repression of TLR-mediated responses. 48 In turn, TLR3/4-activated IRF3 represses LXR transcriptional activity. 49 However, this is, to our knowledge, the first study reporting the regulation of IRF8 expression by LXR␣.
Collectively, our findings uncover an original LXR␣modulated mechanistic axis LXR␣/IRF8/PU.1 in macrophages that may have important repercussions for atherosclerosis and other macrophage-centered diseases.
